Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

BACKGROUND: The identification of somatic mutations in the gene encoding the serine–threonine protein kinase B-RAF (BRAF) in the majority of melanomas offers an opportunity to test oncogene-targeted therapy for this disease. METHODS: We conducted a multicenter, phase 1, dose-escalation trial of PLX4...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Flaherty, Keith T., Puzanov, Igor, Kim, Kevin B., Ribas, Antoni, McArthur, Grant A., Sosman, Jeffrey A., O'Dwyer, Peter J., Lee, Richard J., Grippo, Joseph F., Nolop, Keith, Chapman, Paul B.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2010
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3724529/
https://ncbi.nlm.nih.gov/pubmed/20818844
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1002011
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares